Drug Profile
Research programme: thrombin receptor inhibitors - Millennium/Ortho-McNeil
Alternative Names: Thrombin receptor inhibitors research programme - Millennium/Ortho-McNeilLatest Information Update: 21 Mar 2002
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals; Ortho-McNeil
- Class
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemic heart disorders; Reperfusion injury; Stroke
Most Recent Events
- 21 Mar 2002 COR Therapeutics has been acquired by, and integrated into, Millennium Pharmaceuticals
- 28 Feb 2002 Discontinued - Preclinical for Ischaemic heart disorders in USA (unspecified route)
- 28 Feb 2002 Discontinued - Preclinical for Reperfusion injury in USA (unspecified route)